Skip to main content
If you have any questions or are interested in participating in a clinical trial, please call 1-866-462-9371 or send an e-mail to kidneytrials@unc.edu

Are you interested in participating in a clinical trial?

View UNC Kidney studies at Research for Me (UNC based website)

View trials all over the country for nephrotic syndrome at Kidney Health Gateway

Are you interested in referring a patient for a clinical trial?

View Current Clinical Trials 

What is a Clinical Trial?

In clinical trials, researchers test new ways to prevent, detect, or treat disease. Treatments might be new drugs or combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. Clinical trials can also test other aspects of care, such as ways to improve the quality of life for people with chronic illnesses.

A well-designed clinical trial is the gold standard for proving that a treatment or medical approach works, but clinical trials can’t always be used. For example, scientists can’t randomly assign people to live in different places, or ask people to start smoking or eating an unhealthy diet. Clinical trials are conducted in phases:

Phase I: Find out whether a medical approach (e.g., drug, diagnostic test, device) is safe, identify side effects, and figure out appropriate doses. Typically fewer than 100 subjects.

Phase II: Start testing whether a medical approach works. Continue monitoring for side effects; get information that goes into designing a large, phase III trial. Typically 100-300 subjects.

Phase III: Prove whether a medical approach works; continue monitoring side effects. May enroll as many subjects as needed – can be 1,000 or more.

Phase IV: When a medical approach is being marketed, continue gathering information on its effects. May enroll thousands of subjects.

SOURCE

Resources

Learn more about research at UNC: https://researchforme.unc.edu/index.php/learn
Printable Questions to ask about the research study: https://researchforme.unc.edu/index.php/learn

 

Current Trials at UNC

Click on the names below to read more about current clinical trials.
ANCA Vasculitis (Anti-neutrophil cytoplasmic antibody)

CD5 WATCH: Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

Principal Investigator
Vimal Derebail, MD
vimal_derebail@med.unc.edu

Study Coordinators
Sandy Grubbs, MSN, RN
sandy_grubbs@med.unc.edu

Link: https://clinicaltrials.gov/ct2/show/NCT03906227 

CKD (Chronic Kidney Disease)

FSGS (Focal Segmental Glomerulosclerosis)

PODO: A phase 1, 12 week, adaptive, open label, sequential cohort study to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.
Phase 2 Trial

Principal Investigator
Amy Mottl, MD
amy_mottl@med.unc.edu 

Study Coordinators
Sandy Grubbs, RN
sandy_grubbs@med.unc.edu 

Link: https://clinicaltrials.gov/ct2/show/NCT03448692  

 

Treatment of Drug-resistant FSGS Using the LIPOSORBER® LA-15 System in Adults and Children
Post-Approval

Principal Investigator
Koyal Jain, MD
koyal_jain@med.unc.edu 

Study Coordinators 
Anne Froment, MSW
anne_froment@med.unc.edu

Link – Adults: https://clinicaltrials.gov/ct2/show/NCT04065438

Link – Pediatrics: https://clinicaltrials.gov/ct2/show/NCT02235857

IgA Nephropathy

Safety and Efficacy Study of VIS649 for IgA Nephropathy
Phase 2 Trial

Principal Investigator
Koyal Jain, MD
koyal_jain@med.unc.edu

Study Coordinators
Anne Froment, MSW
anne_froment@med.unc.edu

Link: https://clinicaltrials.gov/ct2/show/NCT04287985 


Safety and Efficacy of Ravulizumab in Participants with IgA Nephropathy
Phase 2 trial

Principal Investigator
Amy Mottl, MD
amy_mottl@med.unc.edu

Study Coordinators
Anne Froment, MSW
anne_froment@med.unc.edu

Link: https://clinicaltrials.gov/ct2/show/NCT04564339

Lupus Nephritis

MiSLE: A Phase 2 sequential dose-escalation study evaluating the safety and feasibility of allogeneic umbilical cord derived mesenchymal stromal cells (MSC) for the treatment of adults with treatment refractory lupus
Phase 2 Trial

Principal Investigator
Saira Sheikh, MD
szsheikh@email.unc.edu

Study Coordinators
Sandy Grubbs, RN
sandy_grubbs@med.unc.edu 

Link: https://clinicaltrials.gov/ct2/show/NCT02633163 


Safety and Efficacy of Ravulizumab in Participants with Lupus Nephritis
Phase 2 trial

Principal Investigator
Amy Mottl, MD
amy_mottl@med.unc.edu

Study Coordinators
Anne Froment, MSW
anne_froment@med.unc.edu

Link: https://clinicaltrials.gov/ct2/show/NCT04564339

Membranous Nephropathy

REBOOT: Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Phase 2 Trial

Principal Investigator
Vimal Derebail, MD
vimal_derebail@med.unc.edu

Study Coordinators
Anne Froment, MSW
anne_froment@med.unc.edu 

Link: https://clinicaltrials.gov/ct2/show/NCT03949855

 

More Information for Providers
Clinical Research Enrolling